Oracea launches as Apprilon in Canada

Written by on February 28, 2013 in Galderma, Oracea (40mg doxycycline) with 0 Comments

galderma_logo

A press release today from Galderma confirms that they will be marketing the product known in the US as Oracea under the name Apprilon in Canada.

All of the same precautions and prescription details for Apprilon are the same as for Oracea, i.e. it is the exact same modified-release capsule, 40 mg doxycycline.

First of its kind rosacea therapy now available in Canada

Two million Canadians suffer from this chronic inflammatory skin disease; March is Rosacea Awareness Month

THORNHILL, ON, Feb. 27, 2013 /CNW/ – Galderma Canada Inc. today announced Apprilon, an innovative, anti-inflammatory rosacea treatment, is now available for prescription in Canada.

Apprilon (Doxycycline Modified-Release Capsule, 40 mg) is the first and only oral, once-daily therapy designed specifically to treat the bumps and pimples associated with rosacea, and does not cause complications associated with long-term antibiotic use.

Recent evidence suggests rosacea is primarily an inflammatory condition, not a bacterial infection. Apprilon is the only medication that reduces the inflammatory response in patients with rosacea without producing drug concentrations required to treat bacterial diseases. 

Each Apprilon capsule contains two types of beads that together provide a dose of 40 mg of doxycycline, an antibiotic in the tetracycline family.

The immediate-release beads contain 30 mg of doxycycline and the delayed-release beads contain 10 mg of doxycycline. 

Clinical studies show the combination of immediate and delayed-release beads keeps Apprilon at a very low dose that will not produce antibiotic resistance over the long term.

Marketed as Oracea in the United States, the availability of Apprilon in Canada reinforces Galderma’s commitment to providing novel skin care treatment options.

Apprilon is now available for prescription across Canada.  Patients should speak with their family doctor or dermatologist to learn more about Apprilon and its suitability for their skincare needs.

Last month Rosacea News reported that Efracea had been approved for use in Canada, but now it is clear that the plan was to market this low dose antibiotic as Apprilon.

Oracea is marketed as Efracea in the UK and Europe.

Related Articles

 

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Subscribe

If you enjoyed this article, subscribe now to receive more just like it.

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave a Comment

Top